{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:04:12Z","timestamp":1783652652558,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011475","name":"Cholangiocarcinoma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011475","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Foundation for Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1K08CA236874"],"award-info":[{"award-number":["1K08CA236874"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cmghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.jcmgh.2024.01.006","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T04:12:03Z","timestamp":1705810323000},"page":"853-876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in Cholangiocarcinoma"],"prefix":"10.1016","volume":"17","author":[{"given":"Emilien J.","family":"Loeuillard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah E.","family":"Stumpf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Willhite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred Rakhshan","family":"Rohakhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernadette A.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rondell P.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory L.","family":"Smoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2709-3003","authenticated-orcid":false,"given":"Sumera I.","family":"Ilyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmgh.2024.01.006_bib1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrc.2017.28","article-title":"Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy","volume":"17","author":"von Karstedt","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.276.5309.111","article-title":"The receptor for the cytotoxic ligand TRAIL","volume":"276","author":"Pan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib3","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1093\/emboj\/16.17.5386","article-title":"TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL","volume":"16","author":"Walczak","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib4","first-page":"2770","article-title":"Molecular cloning and functional analysis of the mouse homologue of the KILLER\/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor","volume":"59","author":"Wu","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib5","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.molcel.2017.01.021","article-title":"The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2","volume":"65","author":"Hartwig","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1084\/jem.193.6.661","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis","volume":"193","author":"Smyth","year":"2001","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib7","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1172\/JCI74056","article-title":"ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis","volume":"124","author":"Condamine","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib8","article-title":"Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer","volume":"9","author":"Nalawade","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1074-7613(00)80401-X","article-title":"TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB","volume":"7","author":"Schneider","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib10","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/cdd.2013.28","article-title":"Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family","volume":"20","author":"Azijli","year":"2013","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib11","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib13","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib15","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1172\/JCI137110","article-title":"Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"Loeuillard","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-derived suppressor cells coming of age","volume":"19","author":"Veglia","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib17","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.celrep.2017.10.104","article-title":"CCR5 directs the mobilization of CD11b(+)Gr1(+)Ly6C(low) polymorphonuclear myeloid cells from the bone marrow to the blood to support tumor development","volume":"21","author":"Hawila","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib18","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2006.08.5829","article-title":"Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine","volume":"25","author":"Filipazzi","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3Kgamma is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00262-013-1508-5","article-title":"Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab","volume":"63","author":"Meyer","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41556-019-0298-1","article-title":"Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response","volume":"21","author":"Salvagno","year":"2019","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib22","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib23","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/hep.27687","article-title":"IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism","volume":"61","author":"Yamada","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib24","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.18632\/oncotarget.23638","article-title":"YAP-associated chromosomal instability and cholangiocarcinoma in mice","volume":"9","author":"Rizvi","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib25","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/0008-5472.CAN-11-3596","article-title":"Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma","volume":"72","author":"O'Dell","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib26","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23972","article-title":"Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth","volume":"2","author":"Liu","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-020-03116-4","article-title":"Gut-licensed IFNgamma(+) NK cells drive LAMP1(+)TRAIL(+) anti-inflammatory astrocytes","volume":"590","author":"Sanmarco","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib28","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.immuni.2010.05.010","article-title":"Tumor-induced tolerance and immune suppression depend on the C\/EBPbeta transcription factor","volume":"32","author":"Marigo","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib29","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1172\/JCI26322","article-title":"IKK\/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy","volume":"115","author":"Luo","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.molcel.2015.07.032","article-title":"NF-kappaB-independent role of IKKalpha\/IKKbeta in preventing RIPK1 kinase-dependent apoptotic and necroptotic cell death during TNF signaling","volume":"60","author":"Dondelinger","year":"2015","journal-title":"Mol Cell"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib31","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.immuni.2020.05.001","article-title":"Single-cell RNA sequencing of tumor-infiltrating NK cells reveals that inhibition of transcription factor HIF-1alpha unleashes NK cell activity","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib33","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/onc.2016.288","article-title":"Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma","volume":"36","author":"Murakami","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib32","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1038\/sj.onc.1210985","article-title":"Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis","volume":"27","author":"Geserick","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib34","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.4049\/jimmunol.1303242","article-title":"TRAIL-receptor costimulation inhibits proximal TCR signaling and suppresses human T cell activation and proliferation","volume":"193","author":"Lehnert","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib35","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41568-022-00546-2","article-title":"Therapeutic targeting of tumour myeloid cells","volume":"23","author":"Barry","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib36","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1038\/sj.onc.1206520","article-title":"TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB","volume":"22","author":"Ehrhardt","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/cdd.2013.36","article-title":"The dark side of TRAIL signaling","volume":"20","author":"Fulda","year":"2013","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib38","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1111\/febs.15637","article-title":"The multifaceted role of TRAIL signaling in cancer and immunity","volume":"288","author":"Cardoso Alves","year":"2021","journal-title":"FEBS J"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib39","doi-asserted-by":"crossref","first-page":"G129","DOI":"10.1152\/ajpgi.00242.2005","article-title":"Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells","volume":"290","author":"Ishimura","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib40","article-title":"Obesity diminishes response to PD-1-based immunotherapies in renal cancer","volume":"8","author":"Boi","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib41","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1202390","article-title":"Programmed death ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction","volume":"5","author":"Hendriks","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib42","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00262-014-1548-5","article-title":"Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8alpha dendritic cells","volume":"63","author":"James","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib43","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/s41467-018-07654-4","article-title":"Induction of immunosuppressive functions and NF-kappaB by FLIP in monocytes","volume":"9","author":"Fiore","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76079-1","article-title":"Pharmacological targeting of c-FLIP(L) and Bcl-2 family members promotes apoptosis in CD95L-resistant cells","volume":"10","author":"Konig","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib45","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s43018-022-00462-2","article-title":"cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis","volume":"3","author":"Wang","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031085","article-title":"Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)\/CpG immunotherapy","volume":"7","author":"Norian","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1008942828960","article-title":"Conditional gene targeting in macrophages and granulocytes using LysMcre mice","volume":"8","author":"Clausen","year":"1999","journal-title":"Transgenic Res"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib48","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/gut.47.5.721","article-title":"Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver","volume":"47","author":"Tannapfel","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib49","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1005412626515","article-title":"Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver","volume":"45","author":"Tannapfel","year":"2000","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib50","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/0008-5472.CAN-21-2556","article-title":"In\u00a0vivo modeling of patient genetic heterogeneity identifies new ways to target cholangiocarcinoma","volume":"82","author":"Younger","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib51","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jhep.2019.05.027","article-title":"Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis","volume":"71","author":"Wang","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib52","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/gutjnl-2021-324109","article-title":"GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity","volume":"71","author":"Ruffolo","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib53","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1038\/s41467-022-30599-8","article-title":"Publisher correction: single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma","volume":"13","author":"Song","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111384","article-title":"Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis","volume":"40","author":"Keenan","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib55","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1038\/s41467-022-35291-5","article-title":"Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer","volume":"13","author":"Ma","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib56","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jhep.2020.05.039","article-title":"Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma","volume":"73","author":"Zhang","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib57","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccell.2019.08.007","article-title":"Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer","volume":"36","author":"Ma","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib58","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib60","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.jcmgh.2024.01.006_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","article-title":"DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data\u00a0Using Artificial Neaerest Neighbors","volume":"8","author":"McGinnis","year":"2019","journal-title":"Cell Systems"}],"container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X24000055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X24000055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:35:17Z","timestamp":1762454117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352345X24000055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2352345X24000055"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmgh.2024.01.006","relation":{},"ISSN":["2352-345X"],"issn-type":[{"value":"2352-345X","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in Cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Cellular and Molecular Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmgh.2024.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}